Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Default

Display 15 Products per page

Market Spotlight: Gastrointestinal Stromal Tumor (GIST)

$1,318.00

This Market Spotlight report covers the Gastrointestinal Stromal Tumor (GIST) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and drug-specific revenue forecasts.
December 9, 2022
Find out more
Disease Analysis: Type 2 Diabetes
Read More
Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.
December 9, 2022
Find out more
Disease Analysis: Pulmonary Hypertension
Read More
Pulmonary hypertension (PH) is a life-threatening and often fatal disease characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to a progressive increase in pulmonary vascular resistance (PVR) and, ultimately, the development of right ventricular (RV) dysfunction. Cornerstone histopathological features of the PH vasculopathy include intimal thickening, concentric hypertrophy, and perivascular fibrosis of distal pulmonary arterioles.
December 9, 2022
Find out more
Market Spotlight: Irritable Bowel Syndrome (IBS)

$1,318.00

This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
December 8, 2022
Find out more
Extremity Replacement Implants

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for extremities replacement implants. Market forecasts and competitive analyses are provided for the shoulder, elbow, ankle, and small joint arthroplasty devices markets. Geographic segments covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.
December 8, 2022
Find out more
Market Spotlight: Neuropathic Pain

$1,318.00

This Market Spotlight report covers the neuropathic pain market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
December 7, 2022
Find out more
Disease Analysis: Prostate Cancer
Read More
Prostate cancer occurs when malignant cells originate in the prostate gland. The vast majority of prostate cancers are adenocarcinomas, but other less common types include sarcomas, small cell carcinomas, neuroendocrine tumors, and transitional cell carcinomas. Some prostate cancers can grow and spread quickly, but many are relatively indolent. Because of this, depending on patient age and other co-morbidities, some prostate cancer patients may not receive active treatment for the disease during their lifetime.
December 7, 2022
Find out more
Disease Analysis: Hepatitis C
Read More
Hepatitis C is a liver disease caused by chronic infection with hepatitis C virus (HCV), a hepacivirus belonging to the Flaviviridae family. HCV infects hepatocytes and is the leading cause of cirrhosis and hepatocellular cancer (HCC). Approximately 15−45% of people infected with HCV will spontaneously clear the virus, but the remaining 55−85% will develop chronic HCV infection. For those chronically infected with HCV, the risk of cirrhosis increases by 15–30% within 20 years.
December 7, 2022
Find out more
Market Spotlight: Atrial Fibrillation

$1,318.00

This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
December 7, 2022
Find out more
Disease Analysis: Melanoma
Read More
Melanoma accounts for just 1% of all skin cancer cases, but is responsible for the majority of skin cancer-related deaths. Melanoma occurs when melanocytes – pigment-producing cells of the skin that are intercalated in the basal cell layer – become malignant. Although surgical excision is a potentially curative option for many melanoma patients, the disease can disseminate rapidly. Currently, only 27.3% of patients diagnosed with distant metastatic melanoma survive for five years, compared to about 99.0% of those with localized disease. Although 83% of patients present with localized disease, approximately one quarter to one third of these patients will eventually experience disease recurrence.
December 6, 2022
Find out more
Market Spotlight: Mantle Cell Lymphoma

$1,318.00

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
December 6, 2022
Find out more
Disease Analysis: Cystic Fibrosis
Read More
Cystic fibrosis, caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein, is a rare and life-limiting genetic disorder that is characterized by thick, sticky mucus and pulmonary complications.
December 2, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL)
Read More
The CLL treatment paradigm has changed significantly over the past five years, with targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors displacing chemotherapy-based treatments for most patients who have CLL.
December 1, 2022
Find out more
Disease Analysis: Renal Cell Carcinoma (RCC)
Read More
Sutent is set to lose ground due to both newer, more effective treatments and imminent biosimilar erosion. Previously the SOC across many treatment settings, the pivotal trials of several newer therapies, which include checkpoint inhibitors Keytruda, Opdivo, and Bavencio, and the RTK inhibitor Cabometyx, have demonstrated significant clinical benefit over Sutent in the first-line setting. Keytruda and Cabometyx have also demonstrated benefit over Sutent in subsequent-line settings.
December 1, 2022
Find out more
Disease Analysis: Bipolar Disorder
Read More
BD is a multifactorial psychiatric mood disorder influenced by social, environmental, and genetic risk factors underlying its etiology. The disorder is characterized by fluctuating mood states, such as mania and depression, interspersed with periods of wellbeing over days and weeks. BD describes a range of disease subtypes, including BD type I, BD type II, and cyclothymia.
November 30, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *